MWNA
IGMS

Marshall Wace North America’s IGM Biosciences IGMS Stock Holding History

Marshall Wace North America’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,090
Closed -$3M – 1597
2021
Q1 		$3M Buy
+39,090
New +$3.56M 0.01% 702

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace North America's IGMS Position: Q2 2021 in Review

Marshall Wace North America sold out of IGM Biosciences (IGMS) in Q2 2021, closing a stake of 39,090 shares — an estimated $3M sold.

Marshall Wace North America first reported a position in IGMS in Q1 2021 and held it in 1 quarter. The position peaked at $3M in Q1 2021. 104 funds tracked by Wall St. Rank hold IGMS as of Q2 2021.

  • Marshall Wace North America reported no remaining IGM Biosciences position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 39,090 IGM Biosciences shares in Q2 2021, an estimated $3M.
  • Marshall Wace North America first reported a position in IGM Biosciences in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's IGM Biosciences position peaked at $3M in Q1 2021.
  • 104 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.